BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 29467555)

  • 1. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
    Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
    World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
    El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
    Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
    J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
    Fernández Carrillo C; Lens S; Llop E; Pascasio JM; Crespo J; Arenas J; Fernández I; Baliellas C; Carrión JA; de la Mata M; Buti M; Castells L; Albillos A; Romero M; Turnes J; Pons C; Moreno-Planas JM; Moreno-Palomares JJ; Fernández-Rodriguez C; García-Samaniego J; Prieto M; Fernández Bermejo M; Salmerón J; Badia E; Salcedo M; Herrero JI; Granados R; Blé M; Mariño Z; Calleja JL
    Hepatology; 2017 Jun; 65(6):1810-1822. PubMed ID: 28170112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
    Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
    J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt.
    Badawi R; Soliman S; Aboali L; Elkadeem M; Elfert A; Elguindy AMA; Ullah MS; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1300-1305. PubMed ID: 32940191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
    BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
    Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
    J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
    Attia D; Deterding K; Cornberg J; Gebel MJ; Cornberg M; Manns MP; Wedemeyer H; Potthoff A
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):67-74. PubMed ID: 30239347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.
    van Tilborg M; Lieveld FI; Smolders EJ; van Erpecum KJ; de Kanter CTMM; Maan R; van der Valk M; Arends JE; Dofferhoff ASM; Blokzijl H; Bijmolen M; Drenth JPH; de Knegt RJ; Burger DM;
    Aliment Pharmacol Ther; 2017 Nov; 46(9):864-872. PubMed ID: 28881031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A clinical study of antiviral therapy for patients with compensated hepatitis C cirrhosis].
    Xie ZW; Li JP; Guan YJ; Zhang XY; Guo FX; Chen BB; Pan CQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):827-833. PubMed ID: 29325276
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis.
    Bashir MH; Fazili J; Madhoun MF; Kanagala R; Chen S; Nusrat S
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):296-301. PubMed ID: 29200006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.
    Gambato M; Canini L; Lens S; Graw F; Perpiñan E; Londoño MC; Uprichard SL; Mariño Z; Reverter E; Bartres C; González P; Pla A; Costa J; Burra P; Cotler SJ; Forns X; Dahari H
    Liver Int; 2019 May; 39(5):826-834. PubMed ID: 30499631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.
    van der Meer AJ; Maan R; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1168-76. PubMed ID: 26647353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.
    Weiler N; Zeuzem S; Welker MW
    World J Gastroenterol; 2016 Nov; 22(41):9044-9056. PubMed ID: 27895394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
    Hanafy AS; Bassiony MA; Basha MAA
    Hepatol Int; 2019 Mar; 13(2):165-172. PubMed ID: 30758786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.